Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
"AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.
1983423 citationsMarie‐Germaine Bousser, E Eschwège et al.Strokeprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of E Eschwège's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E Eschwège with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E Eschwège more than expected).
This network shows the impact of papers produced by E Eschwège. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E Eschwège. The network helps show where E Eschwège may publish in the future.
Co-authorship network of co-authors of E Eschwège
This figure shows the co-authorship network connecting the top 25 collaborators of E Eschwège.
A scholar is included among the top collaborators of E Eschwège based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with E Eschwège. E Eschwège is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Diouf, Ibrahima, Marie‐Aline Charles, Pierre Ducimetière, et al.. (2010). Evolution of Obesity Prevalence in France. Epidemiology. 21(3). 360–365.93 indexed citations
4.
Fagot‐Campagna, A., Sandrine Fosse‐Edorh, Candice Roudier, et al.. (2009). Characteristics, vascular risk and complications in people with diabetes, in metropolitan France: major improvements between ENTRED 2001 and ENTRED 2007 studies.. 450–455.10 indexed citations
5.
Vauzelle-Kervroëdan, F, F. Javoy, Anne Forhan, P Fender, & E Eschwège. (2008). Pharmacoépidémiologie du diabète : évaluation du bon usage des antidiabétiques oraux. Diabetes & Metabolism. 26. 63–68.2 indexed citations
Vauzelle-Kervroëdan, F, Anne Forhan, F. Javoy, P Fender, & E Eschwège. (1999). [Pharmacoepidemiology of diabetes: contribution of a survey of health insurance cases].. PubMed. 25(2). 163–71.1 indexed citations
Costagliola, Dominique, et al.. (1994). Management of type 2 diabetes mellitus in France: attitudes and practices among a representative sample of general practitioners.. PubMed. 20(5). 458–64.4 indexed citations
19.
Bousser, Marie‐Germaine, E Eschwège, M Haguenau, et al.. (1983). "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.. Stroke. 14(1). 5–14.423 indexed citations breakdown →
20.
Eschwège, E, et al.. (1978). [Descriptive epidemiology of diabetes mellitus].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 15–6.3 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.